GlassScriptPhysician profile
Mark S Waxman
NPI 1396719894
$634.70
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $223 · 2021: $199.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $133.73 | 2019-2021 | |
| Amarin Pharma, INC. | $92.69 | 2019-2021 | |
| Abbvie INC. | $54.18 | 2019-2021 | |
| Redhill Biopharma INC. | $52.21 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $50.74 | 2019-2021 | |
| Allergan, INC. | $40.83 | 2019-2020 | |
| Pfizer INC. | $39.63 | 2020-2021 | |
| Lilly USA, LLC | $38.68 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.90 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.00 | 2019 | |
| Alfasigma USA, INC. | $14.94 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.59 | 2019 | |
| Amgen INC. | $13.42 | 2019 | |
| Horizon Therapeutics Plc | $12.13 | 2021 | |
| Braintree Laboratories, INC. | $12.13 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $11.90 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Waxman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.